Fostering Innovation in the Face of Changes in Today’s Healthcare Environment | BMWS25 Panel

In this BMWS panel, leaders from Takeda, Taiwan BioManufacturing Corp, and Landmark Bio discuss how biopharma organizations can innovate amid accelerating scientific, regulatory, and supply-chain change.

Michael Thien (Former SVP & Head of Pharmaceutical Sciences, R&D, Takeda), Pat Yang (Chairman, Taiwan BioManufacturing Corp), and Ran Zheng (CEO, Landmark Bio) explore how biopharma organizations can drive innovation while navigating today’s disruptive healthcare landscape. They discuss strategies for advancing treatments for rare and ultra-rare diseases, integrating digital tools and automation into modern manufacturing, and fostering cross-functional innovation despite evolving regulatory and supply chain pressures.

Key insights include:
- Approaches to accelerating development for rare and ultra-rare disease therapies
- How digital tools and automation strengthen biomanufacturing capabilities
- Strategies to foster innovation across functions during industry and regulatory change
- Perspectives from leaders shaping the future of advanced therapy development

About BMWS:
The Biomanufacturing World Summit brings together senior manufacturing, technical operations, quality, and bioprocessing leaders to share insights, explore innovation, and advance the future of global biopharma production.

Learn more at https://www.executiveplatforms.com/bmws/

Видео Fostering Innovation in the Face of Changes in Today’s Healthcare Environment | BMWS25 Panel канала Assemble Peer Intelligence